Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 822

1.

A reappraisal of loop diuretic choice in heart failure patients.

Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM.

Am Heart J. 2015 Mar;169(3):323-333. doi: 10.1016/j.ahj.2014.12.009. Epub 2015 Jan 6. Review.

PMID:
25728721
2.

Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators.

Butler J, Fonarow GC, O'Connor C, Adams K, Bonow RO, Cody RJ, Collins SP, Dunnmon P, Dinh W, Fiuzat M, Georgiopoulou VV, Grant S, Kim SY, Kupfer S, Lefkowitz M, Mentz RJ, Misselwitz F, Pitt B, Roessig L, Schelbert E, Shah M, Solomon S, Stockbridge N, Yancy C, Gheorghiade M.

Am Heart J. 2015 Mar;169(3):305-14. doi: 10.1016/j.ahj.2014.12.001. Epub 2014 Dec 17.

PMID:
25728719
3.

Emerging cardiovascular indications of mineralocorticoid receptor antagonists.

Parviz Y, Iqbal J, Pitt B, Adlam D, Al-Mohammad A, Zannad F.

Trends Endocrinol Metab. 2015 Feb 20. pii: S1043-2760(15)00022-3. doi: 10.1016/j.tem.2015.01.007. [Epub ahead of print] Review.

PMID:
25707577
4.

Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.

Pitt B, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Nowack C, Kim SY, Pieper A, Kimmeskamp-Kirschbaum N, Filippatos G.

Eur J Heart Fail. 2015 Feb;17(2):224-32. doi: 10.1002/ejhf.218.

PMID:
25678098
5.

MY APPROACH to patients with heart failure and a normal ejection fraction.

Pitt B.

Trends Cardiovasc Med. 2015 Feb;25(2):164-5. doi: 10.1016/j.tcm.2014.07.009. Epub 2014 Oct 8. No abstract available.

PMID:
25592236
6.

The electromyographic threshold in boys and men.

Pitt B, Dotan R, Millar J, Long D, Tokuno C, O'Brien T, Falk B.

Eur J Appl Physiol. 2015 Jan 15. [Epub ahead of print]

PMID:
25588894
7.

Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.

Rossignol P, Zannad F, Pitt B; Writing group of 10th Global Cardio Vascular Clinical Trialist forum held on December 6th-7th 2013 in Paris, France.

Int J Cardiol. 2014 Dec 20;177(3):731-3. doi: 10.1016/j.ijcard.2014.11.004. Epub 2014 Nov 5.

PMID:
25465821
8.

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction.

Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, Fiuzat M, Zannad F, Pitt B, O'Connor CM.

J Am Coll Cardiol. 2014 Dec 2;64(21):2281-93. doi: 10.1016/j.jacc.2014.08.036. Epub 2014 Nov 24. Review.

PMID:
25456761
9.

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators.

N Engl J Med. 2015 Jan 15;372(3):211-21. doi: 10.1056/NEJMoa1410853. Epub 2014 Nov 21.

PMID:
25415805
10.

Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B.

Circulation. 2015 Jan 6;131(1):34-42. doi: 10.1161/CIRCULATIONAHA.114.013255. Epub 2014 Nov 18.

PMID:
25406305
11.

Mineralocorticoid receptor antagonists for the treatment of hypertension and the metabolic syndrome.

Pitt B.

Hypertension. 2015 Jan;65(1):41-2. doi: 10.1161/HYPERTENSIONAHA.114.04117. Epub 2014 Nov 3. No abstract available.

PMID:
25368029
12.

Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease.

Cheng S, Shah AM, Albisu JP, Desai AS, Hilkert RJ, Izzo J, Oparil S, Pitt B, Solomon SD.

J Hypertens. 2014 Dec;32(12):2479-86; discussion 2486-7. doi: 10.1097/HJH.0000000000000340.

PMID:
25232755
13.

Predictors of contemporary coronary artery bypass grafting outcomes.

Weisel RD, Nussmeier N, Newman MF, Pearl RG, Wechsler AS, Ambrosio G, Pitt B, Clare RM, Pieper KS, Mongero L, Reece TL, Yau TM, Fremes S, Menasché P, Lira A, Harrington RA, Ferguson TB; RED-CABG Executive and Steering Committees.

J Thorac Cardiovasc Surg. 2014 Dec;148(6):2720-6.e1-2. doi: 10.1016/j.jtcvs.2014.08.018. Epub 2014 Aug 14.

PMID:
25218533
14.

Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study).

Maisel A, Xue Y, van Veldhuisen DJ, Voors AA, Jaarsma T, Pang PS, Butler J, Pitt B, Clopton P, de Boer RA.

Am J Cardiol. 2014 Sep 1;114(5):737-42. doi: 10.1016/j.amjcard.2014.05.062. Epub 2014 Jun 19. Erratum in: Am J Cardiol. 2014 Nov 15;114(10):1628.

PMID:
25129066
15.

Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.

Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'Meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD.

Circ Heart Fail. 2014 Sep;7(5):740-51. doi: 10.1161/CIRCHEARTFAILURE.114.001583. Epub 2014 Aug 13.

PMID:
25122186
16.

Spironolactone for heart failure with preserved ejection fraction.

Pfeffer MA, Pitt B, McKinlay SM.

N Engl J Med. 2014 Jul 10;371(2):181-2. doi: 10.1056/NEJMc1405715. No abstract available.

17.

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.

Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, van Veldhuisen DJ, Vincent J, Pitt B, McMurray JJ; Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Study.

Heart. 2014 Nov;100(21):1681-7. doi: 10.1136/heartjnl-2014-305673. Epub 2014 Jul 3.

18.

Geographic variation in heart failure trials: time for scepticism?

Pitt B, Gheorghiade M.

Eur J Heart Fail. 2014 Jun;16(6):601-2. doi: 10.1002/ejhf.112. Epub 2014 May 27. No abstract available.

PMID:
24865962
19.

'Men usually say that HIV testing is for women': gender dynamics and perceptions of HIV testing in Lesotho.

DiCarlo AL, Mantell JE, Remien RH, Zerbe A, Morris D, Pitt B, Abrams EJ, El-Sadr WM.

Cult Health Sex. 2014;16(8):867-82. doi: 10.1080/13691058.2014.913812. Epub 2014 May 22.

PMID:
24854495
20.

A mitochondrial pathway for biosynthesis of lipid mediators.

Tyurina YY, Poloyac SM, Tyurin VA, Kapralov AA, Jiang J, Anthonymuthu TS, Kapralova VI, Vikulina AS, Jung MY, Epperly MW, Mohammadyani D, Klein-Seetharaman J, Jackson TC, Kochanek PM, Pitt BR, Greenberger JS, Vladimirov YA, Bayır H, Kagan VE.

Nat Chem. 2014 Jun;6(6):542-52. doi: 10.1038/nchem.1924. Epub 2014 Apr 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk